Abstract: A method of treating a viral respiratory infection, such as infection by at least one of a SARS virus, a coronavirus or SARS-CoV-2, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent which includes a beta thymosin peptide with amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof.

Abstract: Methods, compositions and kits for treating autophagy mediated diseases and disorders are disclosed as well as methods of treating a subject suffering from chronic granulomatous disease (CGD) by administering an effective amount of a thymosin polypeptide or variant thereof to the subject.

Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.

Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.

Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.

Abstract: The present invention relates to methods for promoting tissue repair, angiogenesis and cell migration. The method of the invention utilizes thymosin ?4 (T?4) peptide to promote tissue repair, angiogenesis and cell migration. The invention further relates to modulating T?4 activity in tissues.

Abstract: An ophthalmic composition for administration to an eye containing 0.001-1000 micrograms per ml by weight of thymosin beta 4 (T?4), or an N-terminal variant, a C-Terminal variant, a conservative variant or an isoform thereof, and one or more of a tonicity agent, a buffering agent, a pH adjusting agent, and a solvent, a method of treating an eye of a human for dry eye syndrome by administering an effective amount of the ophthalmic composition to the eye of the human to treat the dry eye syndrome, and a method of treating a cornea of an eye of a human for corneal epithelial thinning by administering an effective amount of the ophthalmic composition to the cornea to treat corneal epithelial thinning.

Abstract: A composition with a polypeptide including amino acid sequence LKKTET or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.

Abstract: A composition comprising a peptide agent comprising amino acid sequence LKKTET (SEQ. ID NO.: 1) or Thymosin ?4 (T?4) can treat a corneal epithelial wound caused by epithelial debridement.

Abstract: A single unit dosage eye drop formulation including 0.1% to 0.6% by weight Thymosin ?4 (T?4) and an ophthalmically acceptable carrier.

Abstract: Inflammation or damage associated with myocardial events is treated or prevented by administration of an angiogenesis-inducing, anti-inflammatory peptide such as Thymosin ?4, an isoform of Thymosin ?4 or oxidized Thymosin ?4.

Abstract: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in the tissue.

Abstract: A method of treatment for treating, preventing, inhibiting or reducing extracellular matrix build-up in a body tissue or a bodily fluid transport vessel, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET peptide, or a conservative variant thereof, in the tissue.

Abstract: A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and/or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (T?4), an isoform of T?4, an N-terminal fragment of T?4, a C-terminal fragment of T?4, T?4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, T?4ala, T?9, T?10, T?11, T?12, T?13, T?14, T?15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, ?-actinin,

Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.

Abstract: Compositions and methods for treatment of skin utilizing thymosin ?4.

Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.

Abstract: Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin ?4, an isoform of Thymosin ?4, oxidized Thymosin ?4, or T?4 sulfoxide.

Abstract: The present invention relates to methods of treatment for treating or preventing injury to cardiovascular or heart tissue in a subject in need thereof by administering an effective amount of thymosin ?4 (T?4) peptide.

Abstract: Pain or irritation of the eyes, caused by injury due to dry eye syndrome, chemical burns or the like can be accompanied by corneal stromal edema. It has been discovered that administration of thymosin ?4 and/or oxidized thymosin ?4 to cornea in need of treatment of corneal stromal edema is a useful treatment for decreasing such corneal stromal edema.